Key findings

  • Five cell linesspanning estrogen-receptor-positive, HER2-positive, triple-negative and inflammatory breast cancer were killed more effectively when aramchol plus regorafenib was combined with palbociclib or neratinib
  • mTOR inactivatedaramchol plus regorafenib dephosphorylated mTOR and activated the autophagy gatekeeper, effects magnified by palbociclib and seen across every cell line tested
  • ATM to AMPKthis signalling was required to dephosphorylate mTORC1 and activate ATG13; knocking down either kinase prevented both effects
  • Targets beyond the enzymeknocking down the stated target of aramchol did not reproduce its effects on signalling or killing, so aramchol acts on additional targets in these cells

Abstract

Aramchol, an inhibitor of Stearoyl-CoA desaturase, synergizes with the multi-kinase inhibitor regorafenib to kill GI tumor cells in vitro and in vivo. A phase I trial in GI tumor patients combining these drugs will open in 2027. Aramchol preferentially concentrates in tissues with high lipid content. Inflammatory breast cancer has a dismal prognosis and new approaches to treat this form of the disease are needed. A standard of care breast cancer therapeutic, the cyclin-dependent kinase 4/6 inhibitor palbociclib, interacted with aramchol as a single agent and with [aramchol plus regorafenib] in vitro to kill a genetically diverse cohort of breast cancer cells, including inflammatory breast cancer. Aramchol interacted with doxorubicin and docetaxel to kill breast cancer cells. Treatment of breast cancer cells with [aramchol plus regorafenib] caused dephosphorylation of mammalian target of rapamycin, mTORC1 S2448, and increased phosphorylation of autophagy gatekeeper/regulator ATG13 S318, effects that were magnified by inclusion of palbociclib. Primary drug-response signaling from ataxia telangiectasia mutated through the AMP-dependent protein kinase was required to cause both dephosphorylation of mTORC1 and ATG13 activation. Palbociclib interacted with [aramchol plus regorafenib] to cause additional autophagosome formation and autophagic flux. Knock down of: Beclin1/ATG5/LAMP2 (macroautophagy); CD95/FADD (death receptor); or eIF2a (endoplasmic reticulum stress) significantly reduced autophagosome/autolysosome formation, and this was mirrored in data sets obtained when defining drug-induced mechanisms of cell death. Our in vitro data conclude that aramchol, alone or combined with regorafenib, has potential to become a new approach to enhance the efficacy of standard of care breast cancer therapeutics.

Introduction

Aramchol is a semi-synthetic bile acid that was initially developed for the treatment of hepatic liver diseases such as Metabolically Associated steatohepatitis (MASH).1 Aramchol inhibits Stearoyl-CoA desaturase (SCD1), with downstream effects including elevated fatty acid oxidation and enhanced glutathione levels.2–6 More recently, we have studied the biology of aramchol as an oncology therapeutic. In this work, aramchol was shown to kill GI tumor cells an effect which was enhanced by the multi-kinase inhibitor regorafenib. Regorafenib inhibits RAF1, BRAF and Class 3 receptor tyrosine kinases.7,8 A phase I trial will open in early 2027 combining aramchol and regorafenib, at Massey Comprehensive Cancer Center, Virginia Commonwealth University, Richmond, Virginia, USA, recruiting recurrent hepatoma, cholangiocarcinoma and colon cancer patients.

There are multiple distinct molecular signatures which comprise the disease called “breast cancer.”9–11 Most commonly presenting are breast cancers that rely on estrogen receptor signaling, and they have been successfully treated using drugs preventing activation of the receptor, with > 90% of estrogen receptor positive patients surviving for at least 5 years.9–11 On the other hand, inflammatory breast cancer (IBC), although less commonly found, is a chemotherapy resistant disease with a ~20% survival after 5 years.12,13 Hence, novel approaches that can target IBC are urgently needed.

From PK/PD analyses in male mice performed by Galmed as part of drug development, it was discovered that aramchol specifically concentrates in the liver and in adipose tissues. As the breast is glandular adipose tissue, we reasoned that tumors of the female breast would represent a natural target population of malignancies to define a portion of the anti-tumor actions of aramchol. Furthermore, as the liver represents a major site of metastasis for mammary cancers, our approaches using aramchol could theoretically target both primary disease and secondary sites.

Palbociclib is an inhibitor of cyclin dependent kinase 4 and 6, and is an approved standard of care drug for the treatment of estrogen receptor and HER2 positive breast cancers.9,14,15 Approximately 10% of patients are de novo resistant to the drug.14,15 As a single agent palbociclib prolonged progression free survival (PFS) without significantly extending overall survival (OS) whereas in subsequent studies palbociclib combined with anti-estrogen receptor endocrine therapy enhanced both PFS and OS.16 Thus the activity of palbociclib can be significantly enhanced by its inclusion in multi-drug therapeutic combinations.

The present studies were initially based on the hypothesis that the established [aramchol plus regorafenib] combination would interact with established standard of care breast cancer therapeutics, e.g., palbociclib and neratinib, to kill breast cancer cells of diverse molecular signatures. Subsequent studies then focused on the interactions between palbociclib and [aramchol plus regorafenib]. The drugs interacted to inactivate mTOR, enhance macroautophagy and flux, and kill IBC cells.

Materials and Methods

Materials. MCF7, BT474, BT549, SUM149, and SUM190 cells were purchased from the ATCC (Bethesda, MD). Regorafenib, neratinib, palbociclib, doxorubicin and docetaxel were purchased from Selleckchem (Houston, TX). Aramchol was provided by Galmed Pharmaceuticals (Tel Aviv, Israel). Trypsin-EDTA, DMEM, RPMI, penicillin-streptomycin were purchased from GIBCOBRL (GIBCOBRL Life Technologies, Grand Island, NY). The LC3-GFP-RFP plasmid was obtained from Addgene (Watertown, MA; #117413). Antibodies were purchased from Cell Signaling Technology (Danvers, MA); Abgent (San Diego, CA); Novus Biologicals (Centennial, CO); Abcam (Cambridge, UK); and Santa Cruz Biotechnology (Dallas, TX). No human PDX studies were performed in this manuscript.

Methods. All bench-side Methods used in this manuscript have been previously performed and described in the peer-reviewed references 7, 8, 17-20. Below we briefly describe our Methods.

Detection of cell death by trypan blue assay. Cells, previously growing in log-phase, 5 x 103 per well of a 96 well plate, were permitted to attach and regrow for 24h. After 24h, cells were treated with vehicle control (DMSO), aramchol (20 mM) plus regorafenib (0.5 mM), and other agents, e.g., palbociclib (50 nM), neratinib (50 nM), as in the Figure Legends. At the indicated time points, usually after 24h, floating cells in the media were obtained and attached cells were harvested by trypsinization; the collected cells were isolated by centrifugation. Cell pellets were resuspended in PBS and mixed 1:1 with trypan blue agent. Viability was determined microscopically using a hemocytometer. Five hundred cells from randomly chosen fields were counted and the number of dead cells was counted and expressed as a percentage of the total number of cells counted.7,8,17–20

Transfection of cells with siRNA. Cells were plated as above, and 24h later transfected. For siRNA transfection, 10 nM of the annealed validated siRNA or the negative control (a “scrambled” sequence with no significant homology to any known gene sequences from mouse, rat, or human cell lines) were used. After a further 24h, cells were treated with vehicle control or with drugs to define changes in macroautophagy (see below) and to determine cell viability (see above). Control studies to define the percentage of protein knock down caused by each of the siRNA molecules are presented in Table 1 for SUM149 and SUM190 IBC cells, with invariant ERK2 as a loading control (see below).7,8,17–20

Table 1. Loading control data showing the impact of siRNA knock down on protein expression. Cells were transfected with a scrambled control siRNA (siSCR) or with an siRNA to knock down each specific protein. Immunostaining performed to detect protein levels. Parallel staining for ERK2 was performed as an internal loading control (n = 3 +/-SD).

SUM149SUM190
ProteinERK2ProteinERK2
siSCRsiProteinsiSCRsiProteinsiSCRsiProteinsiSCRsiProtein
SCD1100261001001002510099
ATM1002510010010025100100
AMPKα1002410010010024100100
Beclin11002710010010026100100
ATG5100251001011002510099
CD951002510010010025100100
FADD1002510010010025100100
BAX100251001001002510099
BAK100241001001002410099
BID1002510010010025100100
eIF2α1002410010010024100100

Assessments of autophagosome and autolysosome levels. Cells were transfected with a plasmid to express LC3-GFP-RFP, purchased from Addgene (Waltham, MA #117413). Where appropriate and noted in each Figure Legend, cells were co-transfected with siRNA molecules to define mechanisms of drug action. Twenty-four hours after transfection, cells were treated with vehicle control or the drugs alone or in combination. Cells were imaged at 60X magnification 4h and 8h after drug exposure and the mean number of intense staining [GFP+RFP+] and [RFP+] punctae per cell determined in living cells from >100 randomly selected cells per condition.7,8,17–20

Assessments of changes in protein expression / protein phosphorylation. Cells were treated with vehicle control, aramchol (20 mM) plus regorafenib (0.5 mM), and other agents, e.g., palbociclib (50 nM), neratinib (50 nM), as indicated in the Figure Legends, or the drugs combined for 4h. Cells were fixed in place, permeabilized and subjected to in-cell immunostaining for the indicated proteins / phospho-proteins. Immuno-stained cells were imaged using an Odyssey infrared imager and using its digital software a staining intensity value, minus background, was obtained. ERK2 staining was used as an invariant loading control. The percentage alteration in protein expression / protein phosphorylation caused by the drugs was determined from three independent replicates from separate individual wells (+/-SD).

Data analysis. Comparison of the effects of various treatments was made using a one-way ANOVA for normalcy followed by a two tailed Student’s t-test with multiple comparisons using SigmaPlot 15. Differences with a p-value of < 0.05 were considered statistically significant. Experiments are the means of multiple individual data points per experiment from 3 independent experiments (± SD).

Results

Our initial studies were to test the hypothesis that standard of care breast cancer drugs would interact with the clinically relevant combination of the previously established [aramchol plus regorafenib] therapeutic in GI tumor cells, to kill a genetically diverse cohort of this tumor cell type.7,8

As single agents the irreversible inhibitor of the EGF receptor and HER2, neratinib, and the cyclin dependent kinase inhibitor 4/6 inhibitor, palbociclib, at a concentration approximately 50% of their safe C max in human plasma both caused modest amounts of tumor cell death in the IBC cell lines SUM149 and SUM190 (Figure 1, left). Both drugs interacted with [aramchol plus regorafenib] to cause greater amounts of cell death, with palbociclib being marginally more efficacious than neratinib. Similar cell death data were obtained in MCF7 (estrogen receptor positive), BT474 (estrogen receptor positive and over-expressing the receptor tyrosine kinase HER2) and BT549 (over-expressing the receptor tyrosine the EGF receptor, triple negative breast cancer cells, TNBC) cells (Figure 1, right). Aramchol as a single agent interacted with palbociclib in at least an additive fashion to kill genetically diverse sets of breast cancer cell isolates over a 48h time course (Figure 2). Doxorubicin and docetaxel are standard-of-care IBC therapeutics. Aramchol interacted with doxorubicin and with docetaxel to kill breast cancer cells and also significantly enhanced the lethality of [doxorubicin plus docetaxel] (Figure 3). Thus, aramchol as a single agent or when combined with the regorafenib interacted with multiple standard-of-care drugs to kill breast cancer cells regardless of their pleiotropic genetic background, e.g., estrogen receptor positive, HER2 positive, TNBC or IBC.

Figure 1. Inflammatory, estrogen receptor positive, HER2 positive, and triple negative breast cancer cells are killed by [aramchol plus regorafenib], which is enhanced by palbociclib or neratinib. Breast cancer cells of diverse genetic backgrounds were treated with vehicle control, aramchol plus regorafenib, palbociclib, neratinib or the drugs combined for 24h, per the Methods (n = 3 +/- SD): # p < 0.05 greater than single drug treatments or [aramchol plus regorafenib] treatment.
Figure 2. Inflammatory, estrogen receptor positive, HER2 positive, and triple negative breast cancer cells are killed by aramchol, an effect which is enhanced by the cyclin dependent kinase 4/6 inhibitor palbociclib. Cells were treated with vehicle control, aramchol, palbociclib or the drugs combined as indicated for 24h and 48h, per the Methods (n = 3 +/- SD). # p < 0.05 greater than treatments with palbociclib alone or aramchol alone; ‡ p < 0.05 greater than corresponding values after 24h.
Figure 3. Aramchol enhances the efficacy of doxorubicin and docetaxel in breast cancer cells. Cells were treated with vehicle control, aramchol, regorafenib, doxorubicin (2.5 mM), docetaxel (1 nM) or the drugs combined for 24h and processed as per the Methods (n = 3 +/-SD): # p < 0.05 greater than docetaxel alone or doxorubicin alone; ## p < 0.05 greater than [aramchol plus doxorubicin] or [aramchol plus docetaxel].

We next defined alterations in cell signaling caused by palbociclib, [aramchol plus regorafenib] and the three drugs combined. Notably, in all of the breast cancer cell lines tested, the drugs interacted to cause greater inactivation of mammalian target of rapamycin (mTORC1 / mTORC2), ERK1/2 and AKT alongside the expression of cytoprotective BCL-XL and MCL1 both being reduced and the levels of the cytotoxic BH3 domain proteins BAX and BAK becoming enhanced (Table 2, Table 3, Table 4). ATG13 is the gatekeeper to the formation of autophagosomes. ATG13 S318 phosphorylation was increased by the drugs and elevated endoplasmic reticulum stress signaling was observed, as judged by enhanced eIF2a S51 phosphorylation.

Table 2. The regulation of cell signaling in SUM149 cells by aramchol, regorafenib and palbociclib. Cells were treated with vehicle control, aramchol plus regorafenib, palbociclib or the drugs combined for 4h, per the Methods (n = 3 +/-SD): # p < 0.05 greater than vehicle control; * p < 0.05 less than vehicle control; ** p < 0.05 less than aramchol plus regorafenib alone value; ## p < 0.05 greater than aramchol plus regorafenib alone value; † p < 0.05 palbociclib value greater than aramchol plus regorafenib value.

SUM149 4hVEHA+RPALARP
ATM100101101101
P-ATM S1981100121#103123#
AMPK100100100100
P-AMPK T172100120#104123#
mTOR100103102102
P-mTORC1 S244810073*90*†61**
P-mTORC2 S248110071*89*†62**
ERK2100101100100
Beclin1100121#112#133##
ATG5100121#112#127#
ATG13100101100100
P-ATG13 S318100113#111#121##
AKT10010010099
P-AKT T308100869982
ERK1/210010099100
P-ERK1/2100949487
eIF2α100101101101
P-eIF2α S51100121#111#133##
BCL-XL10081*90*71**
MCL110084*9178*
BAX10010992114#
BAK100121#109127#
ERK2100100101101

Table 3. The regulation of cell signaling in MCF7 cells by aramchol, regorafenib and palbociclib. Cells were treated with vehicle control, aramchol plus regorafenib, palbociclib or the drugs combined for 4h, per the Methods (n = 3 +/-SD): # p < 0.05 greater than vehicle control; * p < 0.05 less than vehicle control; ** p < 0.05 less than aramchol plus regorafenib alone value; ## p < 0.05 greater than aramchol plus regorafenib alone value; † p < 0.05 palbociclib value greater than aramchol plus regorafenib value.

MCF7 4hVEHA+RPALARP
ATM100101101101
P-ATM S1981100121#104124#
AMPK1009999100
P-AMPK T172100122#104125#
mTOR100999999
P-mTORC1 S244810072*90*†60**
P-mTORC2 S248110075*91*†65**
ERK210010010099
Beclin1100121#111#129#
ATG5100119#111#127#
ATG1310010199101
P-ATG13 S318100114#110#121#
AKT100100100100
P-AKT T30810086*9982*
ERK1/210099100101
P-ERK1/2100919587*
eIF2α100100101101
P-eIF2α S51100123#111#130#
BCL-XL10083*90*71**
MCL110086*90*80*
BAX100108106111#
BAK100112#108115#
ERK21009998100

Table 4. The regulation of cell signaling in BT474 cells by aramchol, regorafenib and palbociclib. Cells were treated with vehicle control, aramchol plus regorafenib, palbociclib or the drugs combined for 4h, per the Methods (n = 3 +/-SD): # p < 0.05 greater than vehicle control; * p < 0.05 less than vehicle control; ** p < 0.05 less than aramchol plus regorafenib alone value; ## p < 0.05 greater than aramchol plus regorafenib alone value; † p < 0.05 palbociclib value greater than aramchol plus regorafenib value.

BT474 4hVEHA+RPALARP
ATM100101101101
P-ATM S1981100124#106127#
AMPK10099100100
P-AMPK T172100121#101128#
mTOR1001009999
P-mTORC1 S244810075*90*†64**
P-mTORC2 S248110073*89*†63**
ERK2100100100100
Beclin1100123#110#130#
ATG5100121#107126#
ATG1310099100100
P-ATG13 S318100117#111#126##
AKT100100101101
P-AKT T30810010399101
ERK1/21009910099
P-ERK1/2100949592
eIF2α100100100101
P-eIF2α S51100124#109131#
BCL-XL10079*84*71**
MCL110084*90*82*
BAX100114#107121#
BAK100110#103116#
ERK2100100100100

Transient siRNA knock down of the ataxia telangiectasia mutated (ATM) kinase prevented drug-induced phosphorylation of the AMP-dependent protein kinase alpha subunit (AMPKa) at T172 (Tables 5 and 6). Knock down of AMPKa prevented the drug-induced inactivation of mTORC1 S2448 and mTORC2 S2481 (Tables 5 and 6). Knock down of ATM or AMPKa prevented the increase in ATG13 S318 phosphorylation. The inactivation of mTORC1 and increased phosphorylation of ATG13 S318 predicts for drug-treated cells that will have increased macroautophagy / autophagic flux and greater mitochondrial dysfunction, i.e., reactive oxygen species and cytochrome c release.21–24

Table 5. Signaling by ATM-AMPK is essential for drug-induced decreases in mTORC1 / mTORC2 phosphorylation and enhanced ATG13 phosphorylation in SUM149 cells. Cells were transfected to knock down ATM or AMPKa. Cells were treated with vehicle control, aramchol plus regorafenib, palbociclib or the drugs combined for 4h, per the Methods (n = 3 +/-SD): # p < 0.05 greater than vehicle control; * p < 0.05 less than vehicle control; ** p < 0.05 less than aramchol plus regorafenib alone value; ## p < 0.05 greater than aramchol plus regorafenib alone value; † p < 0.05 palbociclib value greater than aramchol plus regorafenib value.

VEHA+RPALARP
ATMsiSCR100100100100
siATM25252525
siAMPKα100100100100
P-ATM S1981siSCR100121#102123#
siATM26262525
siAMPKα100121102123
AMPKαsiSCR100100101100
siATM100100100100
siAMPKα25262426
P-AMPK T172siSCR100120#103122#
siATM24272529
siAMPKα25302529
mTORsiSCR100100100102
siATM10010099100
siAMPKα9910099100
P-mTORC1 S2448siSCR10075*91†61**
siATM98989899
siAMPKα98979798
P-mTORC2 S2481siSCR10073*89*†63**
siATM97979796
siAMPKα97969796
ATG13siSCR100100100100
siATM99100100100
siAMPKα100100100100
P-ATG13 S318siSCR100115#111#125#
siATM101103102105
siAMPKα100102103105
ERK2siSCR100101100100
siATM100101101100
siAMPKα100100100100

Table 6. Signaling by ATM-AMPK is essential for drug-induced decreases in mTORC1 / mTORC2 phosphorylation and enhanced ATG13 phosphorylation in SUM190 cells. Cells were transfected to knock down ATM or AMPKa. Cells were treated with vehicle control, aramchol plus regorafenib, palbociclib or the drugs combined for 4h, per the Methods (n = 3 +/-SD): # p < 0.05 greater than vehicle control; * p < 0.05 less than vehicle control; ** p < 0.05 less than aramchol plus regorafenib alone value; ## p < 0.05 greater than aramchol plus regorafenib alone value; † p < 0.05 palbociclib value greater than aramchol plus regorafenib value.

VEHA+RPALARP
ATMsiSCR100100100100
siATM24252425
siAMPKα10010010099
P-ATM S1981siSCR100119#101121#
siATM26252525
siAMPKα102122#104126#
AMPKαsiSCR100100100100
siATM100100100100
siAMPKα23262526
P-AMPK T172siSCR100121#102123#
siATM24262630
siAMPKα27292729
mTORsiSCR100100100100
siATM999999100
siAMPKα100100100100
P-mTORC1 S2448siSCR10075*90*63**
siATM10099100101
siAMPKα1009999100
P-mTORC2 S2481siSCR10071*88*60**
siATM97979796
siAMPKα97979797
ATG13siSCR100100100101
siATM100100100100
siAMPKα101100100100
P-ATG13 S318siSCR100114#110#122#
siATM100102102105
siAMPKα100103103107
ERK2siSCR100100101100
siATM100101101101
siAMPKα100101101100

We next defined whether any changes in macroautophagy could be observed. To measure macroautophagy and autophagic flux, we made use of a plasmid that encodes for expression of a fusion protein, LC3-GFP-RFP. In the early autophagosome, both GFP and RFP fluoresce, and yellow vesicles are observed. After the fusion of the autophagosome with a lysosome, followed by its acidification, an autolysosome can be detected examining the numbers of red vesicles, as GFP fluorescence is quenched under acidic conditions. Neratinib, palbociclib and [aramchol plus regorafenib] all increased formation of autophagosomes in IBC cells (Figure 4). The combination of neratinib or palbociclib with [aramchol plus regorafenib] caused significantly more autophagosomes to form. Subsequently, the numbers of autophagosomes declined and at a later timepoint the numbers of autolysosomes increased, again with the combinations of neratinib or palbociclib with [aramchol plus regorafenib] causing formation of the greatest numbers of autolysosomes. Similar data were obtained in MCF7, BT474 and BT549 breast cancer cells (Figure 5).

Figure 4. Aramchol, regorafenib and palbociclib interact to cause autophagosome formation and autophagic flux in SUM149 and SUM190 cells. Cells were transfected to express LC3-GFP-RFP. Cells were treated with vehicle control, aramchol plus regorafenib, palbociclib, neratinib or the drugs combined for 4h and 8h, per the Methods (n = 3 +/-SD). * p < 0.05 less than corresponding value at the 4h time point; # p < 0.05 greater than corresponding values at the 4h time point.
Figure 5. Aramchol, regorafenib and palbociclib interact to cause autophagosome formation and autophagic flux to autolysosomes in MCF7, BT474 and BT549 breast cancer cells. Cells were transfected to express LC3-GFP-RFP. Cells were treated with vehicle control, aramchol plus regorafenib, palbociclib or the drugs combined as indicated for 4h and 8h, per the Methods (n = 3 +/-SD): * p < 0.05 less than corresponding value at the 4h time point; # p < 0.05 greater than corresponding values at the 4h time point.

In SUM149 and SUM190 IBC cells transient knock down of ATM, AMPKa, CD95, FADD, Beclin1 or ATG5 significantly lowered drug-stimulated autophagosome formation and reduced autophagic flux to autolysosomes (Figure 6). Knock down of Beclin1 or ATG5 had the greatest inhibitory effect. Knock down these proteins on drug-induced cell killing was very similar to their effects on macroautophagy. Knock down of Beclin1 or ATG5 lowered drug-induced cell death to a significantly greater extent than that of ATM, AMPKa, FADD and CD95 (Figure 7). Again, very similar cell viability data were also obtained in MCF7, BT474 and BT549 breast cancer cells (Figures 8 and 9).

Figure 6. Signaling by ATM, AMPK, CD95 and FADD play key roles in drug-induced macroautophagy in SUM149 and SUM190 cells. Cells were transfected to express LC3-GFP-RFP and co-transfected to knock down Beclin1, ATG5, ATM, AMPKa, CD95 or FADD. Cells were treated with vehicle control, aramchol plus regorafenib, palbociclib or the drugs combined for 4h and 8h, per the Methods (n = 3 +/-SD): * p < 0.05 less than corresponding value at the 4h time point; # p < 0.05 greater than corresponding values at the 4h time point; § p < 0.05 less than corresponding values in siSCR cells; Ω p < 0.05 greater than corresponding values in cells transfected with siBeclin1 or siATG5.
Figure 7. Signaling by ATM, AMPK, CD95 and FADD play key roles in drug-induced cell death in SUM149 and SUM190 cells. Cells were transfected to knock down Beclin1, ATG5, ATM, AMPKa, CD95 or FADD. Cells were treated with vehicle control, aramchol plus regorafenib, palbociclib or the drugs combined for 24h, per the Methods (n = 3 +/-SD): * p < 0.05 less than corresponding value in siSCR cells; ** p < 0.05 less than corresponding values in siATM and siAMPK cells; # p < 0.05 greater than corresponding value in siSCR cells; ‡ p < 0.05 greater than corresponding values in siBeclin1 or siATG5 cells.
Figure 8. Signaling by ATM, AMPK, CD95 and FADD play key roles in drug-induced macroautophagy in MCF7, BT474 and BT549 breast cancer cells. Cells were transfected to express LC3-GFP-RFP and co-transfected to knock down Beclin1, ATG5, LAMP2, CD95 or FADD. Cells were treated with vehicle control, aramchol plus regorafenib, palbociclib or the drugs combined for 4h and 8h, per the Methods (n = 3 +/-SD): * p < 0.05 less than corresponding value at the 4h time point; # p < 0.05 greater than corresponding value at the 4h time point; § p < 0.05 less than corresponding values in siSCR cells; Ω p < 0.05 greater than corresponding values in cells transfected with siBeclin1 or siATG5.
Figure 9. Signaling by ATM, AMPK, CD95 and FADD play key roles in drug-induced cell death in MCF7 and BT474 cells. Cells were transfected with validated siRNA molecules to knock down the expression of Beclin1, ATG5, ATM, AMPKa, LAMP2, CD95 or FADD. Cells were treated with vehicle control, aramchol plus regorafenib, palbociclib or the drugs combined as indicated for 24h, per the Methods (n = 3 +/- SD). * p < 0.05 less than corresponding value in siSCR cells; † p < 0.05 less than Beclin1 knock down alone; § p < greater than corresponding values in siBeclin1.

Based on the data in Tables 1, Table 2 and Table 3, and in Figure 7, Figure 8 and Figure 9, we defined the role of elevated endoplasmic reticulum signaling in the killing process. Additionally, we defined the role of toxic BH3 domain proteins, downstream of CD95/FADD, in facilitating the tumoricidal effects of the drugs. Knock down of eIF2a significantly reduced the amount of tumor cell killing caused by aramchol and regorafenib, palbociclib and the three drug combination (Figure 10). In agreement with data knocking down CD95 or FADD, knock down of BID also significantly reduced tumor cell death.7,8 Individual knock down of the toxic BH3 domain proteins BAK or BAX reduced cell killing, with the double knock down of BAK and BAK being more significantly more efficacious.

Figure 10. Signaling by ATM, AMPK, CD95 and FADD play key roles in drug-induced cell death in SUM149 and SUM190 cells. Cells were transfected with validated siRNA molecules to knock down the expression of BAX, BAK, BID, or eIF2a. Cells were treated with vehicle control, aramchol plus regorafenib, palbociclib or the drugs combined as indicated for 24h, per the Methods (n = 3 +/- SD): ¶ p < 0.05 less than corresponding value in siSCR; * p < 0.05 less than corresponding values in cells transfected with siBAX or siBAK.

The protein Deptor acts to inhibit the activities of both mTORC1 and mTORC2.21–23 In Tables 5 and 6, we demonstrated that a key nodal point of interaction between palbociclib and aramchol plus regorafenib was at the level of mTORC1 and mTORC2. Treatment of cells with palbociclib, but not aramchol plus regorafenib, increased the expression of Deptor (Table 7). Palbociclib interacted with aramchol plus regorafenib to modestly further increase Deptor expression. Knock down of eIF2a significantly reduced the ability of the drugs to enhance Deptor levels. i.e., endoplasmic reticulum stress signaling is required to increase Deptor levels which assist alongside ATM-AMPK signaling to inactivate mTORC1.

Table 7. Knock down of SCD1 does not phenocopy with the biological effects of aramchol-based drug combinations in SUM149 and SUM190 cells. Cells were transfected with a validated siRNA to knock down SCD1. Cells were treated with vehicle control, aramchol plus regorafenib, palbociclib or the drugs combined as indicated for 24h, per the Methods (n = 3 +/- SD): ‡ p < 0.05 greater than corresponding values in siSCR.

siSCRsiSCD1
VEHA+RPalboA+R+PVEHA+RPalboA+R+P
SUM1491.331813.734.74.7‡22.31839
SUM1901.716.312.329.73.7‡20.314.734.3

% cell death

Aramchol was originally developed for the treatment of liver diseases and its stated target was stearoyl-CoA desaturase (SCD1), and that in PK/PD studies conducted by Galmed Ltd. the drug concentrated in the liver and adipose tissues.7,8 As the breast is glandular adipose tissue, we determined whether inhibition of SCD1 using molecular tools phenocopied the use of aramchol. Transient knock down of SCD1 modestly enhanced basal levels of tumor cell death (Table 8). However, no significant impact, above the basal level effect, was observed in drug-treated cells with SCD1 knocked down. This demonstrates that aramchol has additional targets in tumor cells independent of SCD1. Finally, we determined whether transient knock down of SCD1 modified the changes in cell signaling that were observed in Table 2. Knock down of SCD1 did not cause significant changes in the signal transduction alterations we had seen in drug-treated cells (Table 9).

Table 8. Knock down of SCD1 does not significantly alter changes in cell signaling after drug exposure in SUM149 cells. Cells were transfected with a validated siRNA to knock down SCD1. Twenty-four h after transfection, cells were treated with vehicle control, aramchol plus regorafenib, palbociclib or the drugs combined for 4h, per the Methods (n = 3 +/-SD): # p < 0.05 greater than vehicle control; * p < 0.05 less than vehicle control; ** p < 0.05 less than aramchol plus regorafenib alone value; ## p < 0.05 greater than aramchol plus regorafenib alone value.

SUM149 4hsiSCRsiSCD1
VEHA+RPALARPVEHA+RPALARP
ATM100101101101100100100101
P-ATM S1981100117#100121#100123#108125#
AMPK10010099100100100100100
P-AMPK T172100117#104121#100123#106126#
mTOR10010110010110010099101
P-mTORC1 S244810075*9262**10072*9160**
P-mTORC2 S248110073*9262**10072*90*61**
ATG13100100100100100999999
P-ATG13 S318100114#110128##100119#116#126#
ERK2100101100101100100101101

Table 9. Palbociclib as a single agent and more so the [aramchol plus regorafenib plus palbociclib] drug combination increases Deptor expression, which requires endoplasmic reticulum stress signaling. IBC cells were transfected with a validated siRNA to knock down the expression of eIF2a. Twenty-four h after transfection, cells were treated with vehicle control, aramchol plus regorafenib, palbociclib or the drugs combined for 4h, per the Methods (n = 3 +/-SD): # p < 0.05 greater than corresponding vehicle control value.

siSCRsi-eIF2α
VEHA+RPALARPVEHA+RPALARP
SUM149Deptor100106110#114#100100102105
ERK210010010010110099100101
SUM190Deptor100100105110#100100102103
ERK210099100100100100100101

Discussion

The breast is glandular adipose tissue and as aramchol concentrates in lipid rich areas, we hypothesized that developing it as a novel breast cancer therapeutic was logical.

Our earlier studies demonstrated that the inhibitor of stearoyl-CoA desaturase, aramchol, combined with the multi-kinase inhibitor regorafenib in an at least additive fashion to kill multiple GI tumor cell types.7,8 The primary goal of the present studies was to determine whether aramchol plus regorafenib combined with standard of care breast cancer drugs to kill these tumor cells, with a focus on cells derived from inflammatory breast cancer. Aramchol plus regorafenib combined with palbociclib and with neratinib to kill breast cancer cells regardless of their genetics, e.g., estrogen receptor positive, HER2 positive, TNBC expressing the EGF receptor, or IBC.

Aramchol plus regorafenib combined with palbociclib to inactivate mTORC1, mTORC2, eIF2a and to activate ATG13; ATG13 phosphorylation is the causal event in the formation of autophagosomes. The drugs decreased the expression of protective BH3 domain proteins, BCL-XL and MCL1, and increased the expression of toxic BH3 domain proteins BAX and BAK. Aramchol plus regorafenib activated ATM and the AMPK, with AMPK activation being dependent on ATM, however, this signaling module was not further activated by inclusion of palbociclib. In steatohepatitis aramchol is known to regulate the AMPK and mTOR.5 Inactivation of mTORC1 and mTORC2 and activation of ATG13 required signaling by ATM-AMPK. Hence our data demonstrate that a key point of interaction between aramchol plus regorafenib and palbociclib occurs at the level of regulating mTOR.

The regulation of mTORC1 and mTORC2 is based on different multi-protein complexes being formed resulting in different downstream signaling events. Our data showed that both mTORC1 and mTORC2 were both being regulated by aramchol plus regorafenib, palbociclib, and by aramchol plus regorafenib and palbociclib, with the inhibitory effect of aramchol plus regorafenib being significantly greater than the effect of palbociclib as a single agent. Raptor and Rictor are key regulatory proteins in the complexes of mTORC1 and mTORC2, respectively, and two proteins are congruent in both the mTORC1 and mTORC2 complexes; the inhibitor Deptor and mLST8/GL (mammalian lethal with Sec13 protein 8).21–23 Multiple studies show that palbociclib combines with inhibitors of mTORC1 to kill a wide variety of tumor cell types, and that resistance to palbociclib can be mediated by constitutive activation of mTORC1 which is blocked by the mTORC1 inhibitor rapamycin and its analogues.24 However, small-molecule inhibition of mTORC1 by rapalogues causes a compensatory activation of mTORC2, and herein, using a clinically relevant drug concentration for palbociclib we observe modest but significant declines in the activities of both mTORC1 and mTORC2.25 Palbociclib as a single agent enhanced Deptor expression which required endoplasmic reticulum stress signaling via eIF2a. Thus, we have at least three converging signals regulating mTORC1 and autophagy.

Compared to the effects of knocking down proteins whose functions play a role in the regulation of macroautophagy, death receptor signaling appeared to play a less important, though still significant, role as judged by knocking down the expression of CD95 or the docking protein FADD. Activation of CD95 can occur by the binding of FAS ligand, causing receptor trimerization, or independently of FAS ligand by increased tyrosine phosphorylation of the CD95 receptor which induces trimerization.26–28 Upon trimerization CD95 binds to the docking protein FADD to which is associated pro-caspase 8. The docking process causes pro-caspase 8 to auto-catalyze its own cleavage resulting in the release of activated caspase 8. Activated caspase 8 cleaves BID, which results in activated BID, along with other toxic BH3 domain proteins, causing mitochondrial dysfunction which leads to tumor cell death.

When we performed studies examining the roles of BH3 domain proteins we found that BAX and BAK cooperated to cause tumor cell killing, however, the ability of the drugs to interact and cause more cell killing was still observed. When we knocked down BID, the interaction between the drugs to cause more cell death was abolished, i.e., BIG was essential for palbociclib to enhance [aramchol plus regorafenib] efficacy. BID, which it should be noted is in addition to its activation by caspase 8 is also cleaved and activated by lysosomal proteases via the actions of autophagic flux. These mechanisms may explain the relative modest effects of knocking down CD95 or FADD on total cell killing and the drug interactions to cause more death, compared to knocking down BID which suppressed drug-toxicity to a greater extent and abolished the three-drug interaction.

Knock down of eIF2a, blocking the inhibitory effect of endoplasmic reticulum stress signaling on bulk protein translation, but also acting to increase protein levels of Beclin1 and ATG5, reduced the abilities of the drugs alone and in combination to kill breast cancer cells.29,30 This argues that at least one component of the endoplasmic reticulum stress signal is to facilitate a toxic form of macroautophagy. However, we discovered that knock down of CD95 or FADD also significantly reduced autophagosome formation and lowered the amount of flux to autolysosomes to a similar extent as that caused by knock down of Beclin1, ATG5 or LAMP2. FADD not only associates with pro-caspase 8, but also with RIPK1 and RIPK3, and of particular interest for our studies, the ATG5-ATG12 complex.31,32 The co-localization of FADD, ATG5 and RIPK1 results in the cleavage and activation of RIPK1, promoting cell death.33,34 Furthermore, activated RIPK1 via the regulation of TSC2 facilitates AMPK-mediated inactivation of mTOR.35 How CD95/FADD signaling within our aramchol-based drug system regulates macroautophagy and autophagic flux remains presently unknown.

Conclusion

For our in vitro data we conclude that aramchol, through convergent toxic macroautophagy, mitochondrial dysfunction and death receptor signaling, interacted with approved standard-of-care anti-cancer therapeutic drugs to kill inflammatory and other types of breast cancer. It is therefore cogent to consider the future development of aramchol as a novel breast cancer therapeutic.

Declarations

Funding Statement
PD has received funding support from NIH R21 CA283138, "ATG16L1 isoforms and CRC health disparities." PD has received funding support from Galmed Pharmaceuticals, Tel Aviv, Israel, for these studies.
Conflicts of Interest
PD has received funding support from NIH R21 CA283138, "ATG16L1 isoforms and CRC health disparities." PD has received funding support from Galmed Pharmaceuticals, Tel Aviv, Israel, for these studies.
Contributions
MRB, LB and JLR performed the studies. PD directed the studies. We thank Mr. Allen Baharaff for providing salient advice during the performance of these studies. Mr. Allen Baharaff (Galmed) collaborated with PD to develop the studies and critically read the final manuscript.

Abbreviations

  • ERK: extracellular regulated kinase
  • PI3K: phosphatidyl inositol 3 kinase
  • ER: endoplasmic reticulum
  • AMPK: AMP-dependent protein kinase
  • mTOR: mammalian target of rapamycin
  • JAK: Janus Kinase
  • STAT: Signal Transducers and Activators of Transcription
  • MAPK: mitogen activated protein kinase
  • PTEN: phosphatase and tensin homologue on chromosome ten
  • si: small interfering
  • SCR: scrambled
  • VEH: vehicle
  • REGO: regorafenib
  • ARAM: aramchol
  • PALB: palbociclib
  • NER: neratinib
  • DOX: doxorubicin
  • DOCE: docetaxel
  • ATM: Ataxia-Telangiectasia Mutated
  • FADD: FAS-associated death domain protein.

References

  1. Iruarrizaga-Lejarreta M, Varela-Rey M, Fernández-Ramos D, Martínez-Arranz I, Delgado TC, Simon J. et al. Role of Aramchol in steatohepatitis and fibrosis in mice. Hepatol Commun. 2017;1:911-927.
  2. Ratziu V, de Guevara L, Safadi R, Poordad F, Fuster F, Flores-Figueroa J, et al. Aramchol in patients with nonalcoholic steatohepatitis: a randomized, double-blind, placebo-controlled phase 2b trial. Nat Med. 2021;27:1825-1835.
  3. Leikin-Frenkel A, Gonen A, Shaish A, Goldiner I, Leikin-Gobbi D, Konikoff FM, Harats D, Gilat T. Fatty acid bile acid conjugate inhibits hepatic stearoyl coenzyme A desaturase and is non-atherogenic. Arch Med Res. 2010;41:397-404.
  4. Bhattacharya D, Basta B, Mato JM, Craig A, Fernández-Ramos D, Lopitz-Otsoa F, Tsvirkun D, Hayardeny L, Chandar V, Schwartz RE, Villanueva A, Friedman SL. Aramchol downregulates stearoyl CoA-desaturase 1 in hepatic stellate cells to attenuate cellular fibrogenesis. JHEP Rep. 2021;3:100237.
  5. Fernández-Ramos D, Lopitz-Otsoa F, Delacruz-Villar L, Bilbao J, Pagano M, Mosca L, et al. Arachidyl amido cholanoic acid improves liver glucose and lipid homeostasis in nonalcoholic steatohepatitis via AMPK and mTOR regulation. World J Gastroenterol. 2020;26:5101-5117.
  6. Aseem SO, Way G, Wang J, Zhao D, Tai Y, Gurley E, Zeng J, Wang X, Hylemon PB, Huebert RC, Sanyal AJ, Zhou H. Aramchol attenuates fibrosis in mouse models of biliary fibrosis and blocks the TGFbeta-induced fibroinflammatory mediators in cholangiocytes. bioRxiv. 2024:2024.11.06.621880.
  7. Booth L, Booth MR, Roberts JL, Yue Y, Kinsey E, Poklepovic A, Boone D, Cowhart LA, Baharaff A, Dent P. The SCD1 inhibitor aramchol interacts with regorafenib to kill GI tumor cells in vitro and in vivo. Oncotarget. 2025;16:662-678.
  8. Booth MR, Booth L, Roberts JL, Kirkwood JM and Dent P. The SCD1 inhibitor aramchol interacts with regorafenib and metformin to kill GI tumor cells. Oncotarget. 2026: IN PRESS.
  9. Najafizade N, Zarei S, Elhaie M, Roayaei M. Comparative efficacy of Palbociclib and Everolimus with aromatase inhibitors in second line treatment of HR and HER2 negative metastatic breast cancer. Discov Oncol. 2025 Dec 21. doi: 10.1007/s12672-025-04330-0.
  10. Abdelgelil M, Alshangiti A, Taha W, Soliman O, Aldandan R, Alabbas A, Abbas H, Azam F. Understanding the Rare Breast Cancer Subtypes With Variations in Histopathology, Molecular Profiling, Clinical Outcomes and Therapeutic Approaches. Cureus. 2025;17:e96952.
  11. Atallah NM, Quinn C, Rakha E. HER2 expression in breast cancer: evidence gaps and challenges. NPJ Precis Oncol. 2025 Dec 17. doi: 10.1038/s41698-025-01209-9.
  12. Schupp E, Gokun Y, Eckstein J, Stover DG, Jhawar S, Quiroga D, Gatti-Mays ME, Cherian M, Cho MJ, Johnson KCC, LeFebvre H, Chen JC, Elsaid MI, Obeng-Gyasi S. Trimodal therapy is associated with higher overall survival than chemotherapy only in patients with metastatic inflammatory breast cancer. Breast Cancer Res Treat. 2025;215:43.
  13. Wannaphut C, Ponvilawan B, Iwase T, Takahashi Y, Wang X, Ueno NT. Racial and ethnic disparities in survival outcomes among patients with inflammatory breast cancer: a systematic review and meta-analysis. NPJ Breast Cancer. 2025 Dec 13. doi: 10.1038/s41523-025-00879-9.
  14. Nasrazadani A, Tidwell RS, Kai M, Lim B, Valero V, Tripathy D, Saleem S, Debeb BG, Lucci A, Woodward WA, Layman RM; MDACC IBC Clinic and Research Team. Retrospective review of metastatic hormone receptor-positive inflammatory breast cancer patients reveals poor responses to cyclin dependent kinase 4/6 inhibition. Breast Cancer Res. 2025 Dec 10. doi: 10.1186/s13058-025-02162-y.
  15. Alexiou S, Mavrovounis G, Christodoulopoulos G, Perifanou S, Saloustros E. CDK4/6 Inhibitors Plus Endocrine Therapy in Early-Stage HR+/HER2- Breast Cancer: Updated Meta-Analysis of Phase III Trials. Cancers (Basel). 2025;17:3538.
  16. Liu Y, Ren T, Chen X, He Q, Wang X, Tang L. Comparative efficacy and safety of CDK4/6 inhibitors combined with endocrine therapy in HR+/HR2- patients with advanced or metastatic breast cancer: a systematic review and network meta-analysis. BMC Cancer. 2025;25:1535.
  17. Booth MR, Booth L, Roberts JL, West C, Dent P. GZ17-6.02 interacts with carboplatin and etoposide to kill neuroblastoma cells. Anticancer Drugs. 2025;36:478-488.
  18. Booth L, Roberts JL, Spasojevic I, Baker KC, Poklepovic A, West C, Kirkwood JM, Dent P. GZ17-6.02 kills PDX isolates of uveal melanoma. Oncotarget. 2024;15:328-344.
  19. Booth L, Roberts JL, West C, Dent P. GZ17-6.02 kills prostate cancer cells in vitro and in vivo. Front Oncol. 2022;12:1045459.
  20. Dent P, Booth L, Poklepovic A, Von Hoff D, Martinez J, Zhou Y, Hancock JF. Osimertinib-resistant NSCLC cells activate ERBB2 and YAP/TAZ and are killed by neratinib. Biochem Pharmacol. 2021;190:114642.
  21. Jiang J, Zhao C, Yang M, Zhao G, Shu J. Research progress on the regulation mechanism of DEPTOR expression and its role in tumorigenesis. Neoplasma. 2025;72):1-15.
  22. Dibble CC, Cantley LC. Regulation of mTORC1 by PI3K signaling. Trends Cell Biol. 2015;25:545-55.
  23. Caron A, Briscoe DM, Richard D, Laplante M. DEPTOR at the Nexus of Cancer, Metabolism, and Immunity. Physiol Rev. 2018;98:1765-1803.
  24. Fanucci K, Giordano A, Erick T, Tolaney SM, Sammons S. Practical treatment strategies and novel therapies in the phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT)/mammalian target of rapamycin (mTOR) pathway in hormone receptor-positive/human epidermal growth factor receptor 2 (HER2)-negative (HR+/HER2-) advanced breast cancer. ESMO Open. 2024;9:103997.
  25. He J, Zhao J, Quan Y, Hou X, Yang M, Dong Z. Full Activation of Kinase Protein Kinase B by Phosphoinositide-Dependent Protein Kinase-1 and Mammalian Target of Rapamycin Complex 2 Is Required for Early Natural Killer Cell Development and Survival. Front Immunol. 2021;11:617404.
  26. Qiao L, Studer E, Leach K, McKinstry R, Gupta S, Decker R, Kukreja R, Valerie K, Nagarkatti P, El Deiry W, Molkentin J, Schmidt-Ullrich R, Fisher PB, Grant S, Hylemon PB, Dent P. Deoxycholic acid (DCA) causes ligand-independent activation of epidermal growth factor receptor (EGFR) and FAS receptor in primary hepatocytes: inhibition of EGFR/mitogen-activated protein kinase-signaling module enhances DCA-induced apoptosis. Mol Biol Cell. 2001;12:2629-45.
  27. Zhang G, Park MA, Mitchell C, Walker T, Hamed H, Studer E, Graf M, Rahmani M, Gupta S, Hylemon PB, Fisher PB, Grant S, Dent P. Multiple cyclin kinase inhibitors promote bile acid-induced apoptosis and autophagy in primary hepatocytes via p53-CD95-dependent signaling. J Biol Chem. 2008;283:24343-58.
  28. Park MA, Mitchell C, Zhang G, Yacoub A, Allegood J, Häussinger D, Reinehr R, Larner A, Spiegel S, Fisher PB, Voelkel-Johnson C, Ogretmen B, Grant S, Dent P. Vorinostat and sorafenib increase CD95 activation in gastrointestinal tumor cells through a Ca(2+)-de novo ceramide-PP2A-reactive oxygen species-dependent signaling pathway. Cancer Res.;70:6313-24.
  29. Booth L, Roberts JL, Avogadri-Connors F, Cutler RE Jr, Lalani AS, Poklepovic A, Dent P. The irreversible ERBB1/2/4 inhibitor neratinib interacts with the BCL-2 inhibitor venetoclax to kill mammary cancer cells. Cancer Biol Ther. 2018;19:239-247.
  30. Booth L, Roberts JL, Poklepovic A, Dent P. PDE5 inhibitors enhance the lethality of [pemetrexed + sorafenib]. Oncotarget. 2017;8:13464-13475.
  31. Marín-Rubio JL, Vela-Martín L, Fernández-Piqueras J, Villa-Morales M. FADD in Cancer: Mechanisms of Altered Expression and Function, and Clinical Implications. Cancers (Basel). 2019;11:1462.
  32. Pyo JO, Jang MH, Kwon YK, Lee HJ, Jun JI, Woo HN, et al. Essential roles of Atg5 and FADD in autophagic cell death: dissection of autophagic cell death into vacuole formation and cell death. J Biol Chem. 2005;280:20722-9.
  33. Bell BD, Leverrier S, Weist BM, Newton RH, Arechiga AF, Luhrs KA, Morrissette NS, Walsh CM. FADD and caspase-8 control the outcome of autophagic signaling in proliferating T cells. Proc. Natl. Acad. Sci. USA. 2008;105:16677–16682.
  34. Ivanisenko NV, König C, Hillert-Richter LK, Feoktistova MA, Pietkiewicz S, Richter M, Panayotova-Dimitrova D, Kaehne T, Lavrik IN. Oligomerised RIPK1 is the main core component of the CD95 necrosome. EMBO J. 2025;44:3231-3265.
  35. Najafov A, Luu HS, Mookhtiar AK, Mifflin L, Xia HG, Amin PP, Ordureau A, Wang H, Yuan J. RIPK1 Promotes Energy Sensing by the mTORC1 Pathway. Mol Cell. 2021;81:370-385.

Article information

Authors

  • Michael R. BoothDepartment of Biochemistry and Molecular Biology, Sanger Hall 2-002, Virginia Commonwealth University, Richmond VA 23298, USA
  • Laurence BoothDepartment of Biochemistry and Molecular Biology, Sanger Hall 2-002, Virginia Commonwealth University, Richmond VA 23298, USA
  • Jane L. RobertsDepartment of Biochemistry and Molecular Biology, Sanger Hall 2-002, Virginia Commonwealth University, Richmond VA 23298, USA
  • Paul DentDepartment of Biochemistry and Molecular Biology, Sanger Hall 2-002, Virginia Commonwealth University, Richmond VA 23298, USACorresponding author · [email protected]

How to cite

Booth, M. R., Booth, L., et al., 2026. Aramchol as a therapeutic for inflammatory breast cancer in vitro. Medical Research Archives, [online] 14(10). https://doi.org/10.18103/mra.2026.0678

Record

Journal
Medical Research Archives
Section
Research Articles
Published
31 October 2026
ISSN
2375-1924
Downloads
68

Copyright and licence

Published by the European Society of Medicine under a Creative Commons Attribution 4.0 International licence (CC BY 4.0), which permits unrestricted use, distribution and reproduction in any medium, provided the original authors and source are credited.